A direct compression route for 1-(4-fluorobenzyl)-2-chloro-1H-benzo[d]imidazole pharma grade API is evaluated against powder flow and compressibility data before any pilot batch is authorized. The API has the molecular formula C14H10ClFN2 and a molecular mass of 260.69 g/mol. The rigid benzimidazole core carries a C2 chlorine and an N1 4-fluorobenzyl substituent. The halogenated structure can generate cohesive fines after micronization. Particle size and flow data are therefore collected under USP <616> and USP <1174>. A production-scale rotary tablet press with force feeder and B tooling may require a flow function coefficient above 4.0 to maintain tablet weight RSD below 2.0%. The API is screened through a conical mill fitted with a 0.5 mm rasp screen. The blend is prepared by geometric dilution. The drug substance fraction is held at 5.0–25.0 wt% only for low-dose tablet strengths. Microcrystalline cellulose is used at 40.0–70.0 wt% and dibasic calcium phosphate anhydrous at 10.0–25.0 wt% as filler. Crospovidone is added at 3.0–5.0 wt%. Magnesium stearate is sieved and added last at 0.5–1.0 wt%. Lubricant blending is limited to 3–5 min at 25 rpm in a bin blender. Tablet hardness is maintained between 60 N and 120 N to keep disintegration below 15 min under USP <701>. Dissolution is assessed with USP <711> apparatus II at 50 rpm. The terminal dosage form is a film-coated tablet. HPMC/PVA coating at 3.0% weight gain protects against moisture ingress. The direct compression route is not recommended if the API particle size D90 exceeds 250 µm and fines below 75 µm fall below 15%. Published formulation data for this specific molecular configuration are limited. Process development is based on powder rheology control rather than on a fixed commercial formula.

What High-Shear Wet Granulation Variables Govern Batch Uniformity of a Chlorinated Benzimidazole API?

Transfer of the API into a high-shear wet granulation process is justified when direct compression cannot deliver dose uniformity or when tablet friability exceeds 1.0% under USP <1216>. The API is first dry-mixed with lactose monohydrate and microcrystalline cellulose. A typical starting formula contains 10.0–30.0 wt% API, 35.0–55.0 wt% lactose monohydrate, 15.0–25.0 wt% microcrystalline cellulose, 3.0–5.0 wt% croscarmellose sodium, and 2.0–4.0 wt% hypromellose 5 mPa·s binder. The granulation fluid is added at 20.0–30.0 wt% of dry mass. Because the C2 chlorine is a potential leaving group, the binder solution is buffered to a mildly acidic pH if aqueous granulation is used. Ethanol/water 70:30 v/v can reduce water exposure but ethanol is subject to the ICH Q3C Class 3 limit of 5000 ppm in the finished product. The high-shear mixer is run with impeller speed 150–300 rpm and chopper speed 1500–3000 rpm for 4–8 min. Endpoint is controlled by power consumption rather than by time alone. Wet mass is dried in a fluid-bed dryer at inlet air temperature 50–70°C. Loss on drying is targeted at 1.5–2.5%. Dried granules are milled through a 1.0 mm screen at 1000 rpm. The milled granules are blended with extragranular crospovidone and magnesium stearate. Compression is performed on a 16-station rotary tablet press. Tablet ejection force is monitored to stay below 500 N to avoid capping. The terminal finished product is a film-coated tablet or a granule-filled sachet. Wet granulation improves content uniformity for low-dose API fractions but can introduce residual moisture. A residual water content above 3.0% may accelerate hydrolytic degradation of the chlorinated benzimidazole. Stability evaluation under ICH Q1A conditions is required before selecting a commercial granulation solvent.

Dosator Capsule Filling, Segregation, and In-Process Mass Control

Dosator-pin capsule filling is selected for hard gelatin or HPMC capsules when the API dose is below 25 mg and direct compression is not viable. The blend is prepared as a free-flowing powder with bulk density between 0.45 g/mL and 0.75 g/mL under USP <616>. A typical capsule fill formula contains 1.0–10.0 wt% API, 55.0–75.0 wt% mannitol, 10.0–20.0 wt% microcrystalline cellulose, 2.0–5.0 wt% crospovidone, and 0.5–1.0 wt% magnesium stearate. The powder is filled into size 3 or size 4 capsules on a dosator machine operating at 50,000–100,000 capsules/h. Compression force at each dosator station is set to form a powder plug with density 0.65–0.85 g/mL. Fill weight is checked every 15 min with a 5-capsule sample and must remain within ±3.0% of target. Blend segregation is monitored before fill start and after 1 h of continuous operation. If the first and last samples differ by more than 2.0% in assay, the blend is rejected or remixed. The final capsules are dedusted with a rotating brush and passed through a metal detector. Metal check standards are 0.3 mm ferrous, 0.5 mm non-ferrous, and 0.6 mm stainless steel. The terminal product is a hard capsule. HPMC capsules are preferred over gelatin when the climatic zone exceeds 25°C/60% RH during storage because gelatin cross-linking can delay dissolution. Dissolution testing uses USP <711> apparatus I at 100 rpm. C2 chlorine stability in capsule form is monitored for hydrolytic degradants under ICH Q3B thresholds. The degradation product identification threshold is 0.2% or 2 mg for a daily dose from 200 mg to 2 g.

Fluid-bed granulation rather than high-shear mixing is selected when the API is dispersed in a directly compressible granule matrix intended for single-dose sachets or sprinkle administration. The API is first passed through a 0.25 mm screen to break dense agglomerates. A binder solution of hypromellose 3 mPa·s is prepared at 5.0% w/w solids. The granulation charge contains 2.0–20.0 wt% chlorinated benzimidazole API, 45.0–70.0 wt% mannitol, 10.0–20.0 wt% maltodextrin, and 2.0–5.0 wt% croscarmellose sodium. The fluid-bed process is set with inlet air temperature 60–75°C, product temperature 28–34°C, spray rate 10–20 g/min, and atomizing air pressure 1.5–2.5 bar. Granule growth is controlled by droplet size and binder viscosity. Final granules are dried to loss on drying 1.0–2.0%. The dried granules are screened through a 1.0 mm sieve. Granules outside 0.25–1.00 mm are either milled or discarded to maintain content uniformity. Bulk density is measured under USP <616> and should remain between 0.40 g/mL and 0.60 g/mL for automatic sachet filling. The granule blend is filled into aluminum foil sachets at fill weights from 500 mg to 2000 mg. Finished product moisture is kept below 2.0% to reduce electrostatic adhesion and hydrolytic stress on the C2 chlorine. The terminal product is a unit-dose oral granule sachet. Stability is assessed according to ICH Q1A with the sachet in both longitudinal and transverse positions. The barrier of the sachet is verified by seal strength testing under ASTM F88. The seal must withstand a 30 N minimum force before peeling.

When Aseptic Lyophilization Is Required for an Oral-to-Injectable Benzimidazole API

A lyophilization route for 1-(4-fluorobenzyl)-2-chloro-1H-benzo[d]imidazole becomes necessary when aqueous solution stability is insufficient for ready-to-use injection. The API is dissolved in a buffered system with a lyoprotectant. Mannitol is commonly screened at 4.0–6.0% w/v for crystalline cakes and sucrose or trehalose at 5.0–8.0% w/v for amorphous cakes. Drug concentration is evaluated from 1.0 mg/mL to 10.0 mg/mL. The solution pH is selected to maximize solubility while minimizing C2 chlorine displacement. Published data for the hydrolytic rate constant in this specific configuration are limited. The solution is filtered through a 0.22 µm sterilizing-grade membrane housed in a sterilized stainless steel filter assembly. Filtration is performed in an ISO 14644-1:2015 Class 5 area. Vials are washed, depyrogenated at 250°C for 45 min, and filled under aseptic conditions. The filling line operates as a restricted-access barrier system with automatic stopper insertion. The lyophilization cycle begins with nucleation at -45°C. Primary drying is controlled at -20°C and 50–100 µbar for 24–48 h. Secondary drying is ramped to 20–25°C for 6–12 h until residual moisture is below 1.5%. The terminal product is a lyophilized vial for reconstitution with water for injection or sodium chloride 0.9%. Cake collapse is rejected visually. Residual moisture is verified by Karl Fischer titration under USP <921>. Container closure integrity is verified by vacuum decay or dye ingress. The primary closure system is tested under USP <381>. Long-term stability follows ICH Q1A. The lyophilized vial may require refrigerated storage if the dry cake has low glass transition temperature.

Terminal Sterilization of a Chloro-Substituted Benzimidazole Is Not Automatically Preferable to Aseptic Filtration

Steam sterilization is not a default cycle for an injectable formulation of 1-(4-fluorobenzyl)-2-chloro-1H-benzo[d]imidazole API. A terminal sterilization cycle of 121°C for 15 min or F0 ≥ 8 min is acceptable only after forced degradation shows no new impurity above the ICH Q3B reporting threshold. The chlorinated benzimidazole may undergo hydrolytic displacement at the C2 position under superheated aqueous conditions. The product is therefore evaluated in sealed ampoules with an air overlay and in vials with nitrogen overlay. pH is fixed with citrate or acetate buffer at a molarity 10–50 mM. A tonicity agent such as sodium chloride is added to reach 280–320 mOsm/kg under Ph. Eur. 2.2.35. The solution is filtered through 0.22 µm and filled in 2 mL, 5 mL, or 10 mL glass containers. Terminal sterilization is conducted in a saturated steam autoclave with a load probe located in the coldest vessel. The cycle is designed to achieve F0 ≥ 8 min while limiting total heat stress to F0 ≤ 20 min unless stability data support higher values. If terminal sterilization cannot meet the target impurity profile, the route must shift to aseptic filtration in an ISO 14644-1:2015 Class 5 cleanroom with an EU GMP Annex 1 compliant line. The terminal product is a sterile solution for injection. Particulate matter is controlled under USP <788> limits: not more than 6000 particles per container for ≥10 µm and 600 particles per container for ≥25 µm for small-volume injectables.

For a first-in-human or clinical trial batch, the API is split into an oral tablet/capsule stream and an injectable lyophilized or solution stream only after forced degradation confirms route-specific impurity control. The oral solid dose stream uses a direct compression or wet granulation formula as described. The injectable stream uses a buffered solution with pH targeting maximum solubility and minimum C2 chlorine displacement. The two streams are manufactured in separate cleanrooms with separate equipment trains. Cross-contamination risk is controlled by dedicated micronizers, bin blenders, and tableting tools. The cleaning process for 1-(4-fluorobenzyl)-2-chloro-1H-benzo[d]imidazole is validated by swab recovery and rinse sampling. Acceptance limits are calculated from the health-based exposure limit. If no limit is available, a default cleaning limit of 10 ppm in the next product and a visual clean criterion are used. The terminal clinical products are film-coated tablets, hard capsules, sachet granules, and lyophilized vials for reconstitution. Stability is bracketed across 25°C/60% RH and 40°C/75% RH according to ICH Q1A. Each batch is tested for assay, related substances, dissolution, water content, and sterility as applicable. Published data for this specific molecular structure remain limited in public literature. Development batches require process analytical technology for blend uniformity rather than reliance on fixed time points. The batch record closes with a data review of all in-process controls and a final release under 21 CFR 211.165 and 21 CFR 211.166.